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ABSTRACT 
Venlafaxine hydrochloride (VH) is a serotonin-noradrenaline reuptake inhibitor indicated for treatment of depression disorder. It shows low 
biological half-life 5±2 h and low oral bioavailability 45±15 % due to extensive hepatic first-pass metabolism. Frequent administration of VH is 
required to maintain steady state plasma concentration of drug. To overcome hepatic first pass metabolism and to cross blood brain barrier for 
effectively achieving plasma concentration of VH in brain, we envisaged to develop transdermal drug delivery system containin g VH loaded 
polymeric nanoparticles. Effect of solvent systems (SS), penetration enhancers (PE), and VH nanoparticles (VHNPs) on transdermal diffusion of 
drug were studied. VHNPs were prepared by double emulsion solvent evaporation method using high speed homogenizer followed by probe 
sonication. Poly (lactic-co-glycolic acid) and tween 80 were used as polymer and surfactant respectively. Mean particle size, polydispersity 
index, zeta potential, entrapment efficiency of optimized VHNPs were found to be 175.4 nm, 0.109, (-) 24 mV and 56 %.respectively. Scanning 
electron microscopy confirmed spherical shape of drug loaded polymeric nanoparticles. SS comprising 50% PG in EtOH shown maximum flux 
158.67 ± 2.9 (µg/cm2/h) and lag time was found to be 5.60 ±0.16 h. The PE 5 (%v/v) limonene shown maximum flux 200.47±3.6 (µg/cm2/h) 
and lag time 3.17±0.11 h. The flux and lag time in case of VHNPs were found to be 192.24±3.20 (µg/cm2/h) and 4.22±0.14 h respectively. Based 
on flux, clearance and surface area of transdermal patch, a theoretical meaningful plasma level concentration of VH ranging from 12.85 to 128.5 
(ng/mL) can be achieved.  
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INTRODUCTION  
Depression is major psychological condition disturbing 340 
million people worldwide. Present data shows that 9% 
children by age 14 have previously experienced a minimum 
one episode of severe depression, while up to 10% of young 
people are affected by a major depressive disorder [Dinas P. 
et al. 2011]. 
The change in the levels of monoamines serotonin, 
norepinephrine (NE) and dopamine (DA) results in 
depression.   VH is a serotonin-noradrenaline reuptake 
inhibitor, indicated for the treatment of depression [Zhou Y. 
et al. 2015]. Serotonin noradrenaline reuptake inhibitors 
increase the levels of serotonin and noradrenaline in brain 
by blocking their reuptake by nerves. The patients suffering 
from depression shows lowered mood, abstinence from 
pleasure, disturbed food habits, feelings of sorrow, lack of 
concentration in doing things. These problems culminate 
into disability or development of suicidal tendencies [Dinas 
P. et al. 2011]. 
Central nervous system (CNS) shows barrier property for 
drug penetration in brain. Blood brain barrier (BBB) and 
blood cerebrospinal fluid barrier (BCSFB) restricts entry of 
drug in brain [Abbott N 2010]. It is observed that nearly 
100% of large molecules and 98% of small molecules does 
not cross BBB [Tosi G et.al 2008, Bellavance M. 2010]. To 
overcome these difficulties, use of biocompatible drug-
loaded polymeric nanoparticles (PNPs) has been proposed 
[Alexis et al. 2008]. 
VH is a highly water soluble, non-tricyclic antidepressant 
drug. It is serotonin-norepinephrine reuptake inhibitor. It 
involves 5HT1a, 5HT1b and 5HT2a receptors. VH is 5-HT-
dopamine activity modulator, dopamine D2 partial agonist 
and used in treatment of major depressive disorder [Barch D. 
2013]. The steady state biological half-lives of venlafaxine 
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and its active metabolite o-desmethylvenlafaxine are 5 and 
11 h respectively [Gohel M. 2009]. 
The low biological half-life 5 ± 2 hours coupled with low oral 
bioavailability 45 ± 15% due to its extensive first-pass 
metabolism requires frequent drug administration to 
maintain effective plasma concentration of VH. The 
immediate-release oral formulations have side-effects, 
including nausea, insomnia, weakness, drowsiness and 
constipation [Patel H. et al. 2011].  
Drugs used in the treatment of depression are selective 
serotonin reuptake inhibitors, tricyclic antidepressants, 
monoamine oxidase inhibitors, serotonin norepinephrine 
reuptake inhibitors [Tripathi K.D. et al. 2009]. 
Polymeric nanoparticles (PNPs) are solid, colloidal particles 
prepared from biocompatible and biodegradable polymers in 
size between 10-1000 nm where the drug is dissolved, 
entrapped, encapsulated or attached to a nanoparticle 
matrix. Depending upon the method of preparation, 
nanospheres or nanocapsules can be obtained [Anderson J. 
and Shive M. 1977]. Nanocapsules are systems in which the 
drug is confined to a cavity surrounded by a unique polymer 
membrane, while nanospheres are matrix systems in which 
the drug is physically and uniformly dispersed. 
PLGA is a widely used polymer for development of 
nanoparticles because of biocompatibility and potential to 
cross the blood brain barrier. [Acharya S. and Sahoo S., 
2011]. The polymer has been intensively utilized for drug 
delivery and to encapsulate both water-soluble and water-
insoluble drugs [Danhier F. et al. 2012].  
To overcome the hepatic first pass metabolism of VH, it was 
envisaged to develop transdermal drug delivery system 
containing VH loaded polymeric nanoparticles.  
Selection of suitable solvent system is the important step in 
the development of transdermal drug delivery systems. 
Solvent systems comprising ethanol, propylene glycol and 
their binary combinations with water in various proportions 
were studied. The effect of penetration enhancers were 
studied for their effect on ex-vivo skin permeation of VH 
[Panchagnula R et al. 2001]. It was envisaged to compare the 
lag time, and flux values of VH, VHNPs with the solvent 
systems studied in the ex-vivo skin permeation studies. 
MATERIALS AND METHOD 
Materials 
VH was obtained as a gratis sample from Amoli Organics Pvt. 
Ltd. Mumbai, India. Poly (lactic co-glycolic acid) 50:50 
(Molecular weight.24000-38000 Da) was obtained as a gratis 
sample from Evonik India Pvt. Ltd. Mumbai, India. Tween 80 
was obtained from Loba Chemie Pvt. Ltd, India. Ethylene 
vinyl acetate copolymer (EVAC), dibutyl phthalate, ethanol, 
propylene glycol, cineole, limonene, and menthol were 
procured from Merck India Pvt. Ltd, India. Purified water 
was obtained from Milli-Q water purification system. 
Method 
Preparation of polymeric nanoparticles of VH  
Polymeric nanoparticles of VH with PLGA polymer were 
prepared by double emulsion solvent evaporation method. 
The drug, VH was dissolved in distilled water and poly(lactic 
co-glycolic acid) was dissolved in dichloromethane. A w/o 
type emulsion was prepared using various concentrations of 
drug: polymer ratio (Table 1). An accurately weighed amount 
of VH and PLGA polymer were dissolved in 2 mL distilled 
water and 6 mL dichloromethane respectively to form w/o 
type primary emulsion [Bilati U. et al. 2005, Vandervoort J. et 
al. 2002].. 
The primary emulsion was dropwise added using syringe 
into aqueous phase (w) containing tween-80 surfactant 
solutions. The resulting w/o/w type secondary formed was 
kept overnight on continuous magnetic stirring at room 
temperature for complete evaporation of dichloromethane. 
The secondary emulsion was homogenized using a high-
speed homogenizer (IKA Ultra Turrex T18, Germany) at 
12,000 rpm speed for 15 min followed by probe sonication 
(Sonics Vibra Cell ™) at 80 % amplitude for 10 min. 
The polymeric nanoparticles were recovered by 
centrifugation using a refrigerated centrifuge at 20,000 rpm 
for 1 hour at 4 ℃. The supernatant liquids were discarded 
and washed thrice with distilled water to remove the 
adsorbed polymer and drug. The pellets formed of 
nanoparticles was obtained after centrifugation (Remi C24 
Plus). To the formed pellet, a 5 (%w/v) solution of mannitol 
was added as cryoprotectant and filled in glass vials. The 
vials were freeze dried at (-) 40 °C and 750 mm/Hg vacuum 
pressure out for 72 h. The freeze-dried powder product was 
stored in refrigerator in airtight glass container. 
 
Table 1 Formulation of VH loaded polymeric PLGA nanoparticles 
 
 
 
Formulation 
code 
Dose of drug 
(VH) 
Solvents 
Water: DCM 
in 1:3 ratio 
Factor 1 Factor 2 Distilled 
water (q.s.) A: Concentration of 
PLGA polymer 
B:Concentration of 
surfactant tween-80 
mg mL mg %v/v mL 
F1 37.5 2 37.5 2.0 100 
F2 37.5 2 37.5 0.5 100 
F3 37.5 2 75 2.0 100 
F4 37.5 2 75 1.0 100 
F5 37.5 2 75 0.5 100 
F6 37.5 2 112.5 0.5 100 
F7 37.5 2 37.5 1.0 100 
F8 37.5 2 112.5 1.0 100 
F9 37.5 2 112.5 2.0 100 
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Experimental Design  
A full factorial design for two factors at three levels each was 
selected to optimize response of variables. The two factors, 
PLGA sustained release polymer (mg) and tween 80 (%v/v) 
used were varied and the factor levels were suitably coded. 
The particle size, polydispersity index, zeta potential and % 
entrapment efficiency were taken as the response variables. 
In the design, the two factors were evaluated each at three 
levels and experimental trials were performed for possible 
combinations. All other formulation variables and 
processing variables were kept constant throughout the 
studies.                       
The formulae were developed as 9 sets varying the variables 
following 32 full factorial design (3 levels) using Design 
expert software. Dependent variables were Y1 = Particle size 
Y2 = Polydispersity index, Y3= Zeta potential and Y4=% 
Entrapment efficiency. The effect of two independent 
variables PLGA (X1) and Tween-80 (X2) on the responses 
(Y1, Y2, Y3 and Y4) were observed. The levels of all other 
ingredients in the formulation were fixed. 
Characterization of lyophilized VH loaded polymeric 
PLGA Nanoparticles 
Determination of particle size, polydispersity index 
(PDI) and zeta potential  
Lyophilized dried powders of nanoparticles were dispersed 
in distilled water and were kept in an ultrasonicator for 40 
seconds. The mean particle size (z average), zeta potential, 
and polydispersity index (PDI) of aqueous dispersion of VH 
loaded PPNPs were measured by a dynamic light scattering 
method using a Zetasizer Nano ZS-90 (Malvern Instruments, 
Worcestershire, UK). Each value recited was the average of 
determinations on three independent samples of different 
batches of each formulation. If PDI value is closer to 0, it 
indicates narrow size distribution of the particles. PDI of 
optimized dispersion was below 0.5 which indicated 
prepared dispersion is monodisperse and will remain stable 
[Katara R. et.al. 2017]. 
Determination of percent entrapment efficiency and 
percent drug loading  
VH loaded NPs and naive NPs were obtained as pellets after 
centrifugation at 18000 rpm for 60 min at 4 °C. The 
absorbance of the clear supernatant obtained after 
centrifugation of dispersion of drug loaded NPs was 
analyzed in UV spectrophotometer (SHIMADZU 1800) at 
λmax 226 nm against the supernatant obtained from the 
dispersion of naive NPs and was used as blank. The clear 
supernatant also contained the free drug which was 
obtained by washing of the NPs, in the dispersion with 
deionized water. 
The drug entrapment efficiency was determined using the 
equation 1 [Lopez E. et al., 2016]. 
 
 
                     Total amount of VH added – Free VH in supernatant liquid  
 %EE =  ----------------------------------------------------------------------------------- x 100                        --------------- (1) 
                                            Total amount of VH added 
 
Polymer drug interaction studies of lyophilized 
nanoparticles 
The polymer drug interaction studies of lyophilized 
nanoparticles were performed using FT-IR spectroscopy, 
differential scanning calorimetry and x-ray diffraction 
spectroscopy and scanning electron microscopy studies.  
FT-IR spectroscopy 
FT-IR spectrum of VH, PLGA polymer and optimized 
formulation F9 was measured in solid state as potassium 
bromide mixture. (FTIR 8300 Shimadzu, Tokyo, Japan). The 
samples were previously ground and mixed thoroughly with 
potassium bromide, an infrared transparent matrix at 1:100 
(Sample: KBr) ratio, respectively. The spectrum was 
recorded in the range 4000–400 cm-1 [Katara R. et.al. 2017]. 
Differential scanning calorimetry (DSC) 
The sample of VH, PLGA polymer and lyophilized 
nanoparticles of optimized formulation F9 was kept in 
desiccator for 24 h before thermal analysis. An accurately 
weighed sample, 5 mg was hermetically sealed in aluminium 
crucible and DSC analysis was performed using DSC TA-60 
(Shimadzu, Tokyo, Japan) calorimeter heated at constant rate 
of 10 ℃/min. over a temperature range 40 to 400 ℃. An inert 
atmosphere was maintained by purging nitrogen gas at a 
flow rate of 50 mL/min. An empty aluminium pan was used 
as a reference [Katara R. et.al. 2017]. 
X-ray diffraction (X-RD) spectroscopy 
X-ray diffraction spectrum of VH, PLGA and lyophilized 
nanoparticles of optimized formulation F9 was recorded in 
diffractometer (Rigaker Geigerflex, Japan) using Cu-Kα line 
as source of radiation at a voltage of 35 Kv and current 25 
mA. The sample was measured in an angle 2θ range between 
3-80 ⁰ and 0.0053 step size [Katara R. et al. 2017, Sawant et 
al. 2011]. 
Scanning electron microscopic (SEM) study  
Shape and surface morphology of VH PPNPs was visualized 
by scanning electron microscopy (LEO-430 Cambridge and 
U.K). Samples were prepared by lightly sprinkling 
nanoparticles on a double adhesive tape on an aluminum 
stub. The stubs were coated with gold to a thickness of 200 
to 500 Ao under an argon atmosphere using gold sputter 
module in a high vacuum evaporator. The samples were then 
randomly scanned and photomicrographs were recorded at 
different magnifications with SEM [Gulati N. et al. 2014]. 
Ex-vivo skin permeation studies 
For preparation of whole skin, the animal was sacrificed by 
excess inhalation of diethyl ether anesthetic agent. The 
abdominal skin of animal was shaved with the help of animal 
hair remover or clipper in the direction of tail to head 
without causing damage to skin. The shaved skin was excised 
with the help of surgical blade (size 24) fitted in a surgical 
blade holder (size 4). The adhered tissues to the dermis were 
removed with the help of cotton swab moistened with 
isopropyl alcohol. The skin was washed with distilled water, 
wrapped in aluminum foil and stored in freezer at (-) 20 oC 
until further use. The skin was thawed to room temperature. 
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It was kept in thermostatic shaker bath at 37±1 oC 
temperature for 1 h. The receptor fluid phosphate buffer pH 
7.4 containing 0.01% sodium azide was added in the 
receptor medium to retard microbial growth and 
equilibrated to bring it to 37±1 oC temperature [Panchagnula 
R. et al. 2001]. 
The skin was cut into circular pieces to a size of external 
circumference of donor compartment and mounted on 
diffusion cell assembly, keeping stratum corneum side 
towards donor compartment and equilibrated for 1 h. 
Depending on drug solubility of VH, the binary combination 
of ethanol, propylene glycol and their binary combinations 
with water in various proportions were used as solvent 
system for ex-vivo skin permeation studies as shown in table 
2. In the 2 mL solvent system, 37.5 mg was dissolved and 
added in donor phase compartment of diffusion assembly. 
Based on the flux values, optimized solvent system was 
selected showing highest flux as compared to other binary 
solvent systems studied. The effect of penetration enhancer, 
cineole, limonene, menthol were studied by incorporating 
them individually in the optimized binary combination of 
solvent system used in ex- vivo permeation studies. From the 
receptor compartment, 1 mL volume was withdrawn at 0, 1, 
2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and 48 h and replaced with 
equal volume of fresh receptor phase every time to 
determine the amount of drug permeated through the skin.  
Cartesian plots were made taking time in hours on x-axis and 
cumulative amount of drug permeated in receptor fluid on y-
axis The lag time, flux, permeability, and enhancement ratio 
were calculated. Flux values (µg/cm2/h) were calculated 
from the slopes of the steady states of above plots. Lag times 
were calculated from the intercepts of extrapolated steady 
state flux to x-axis. Flux, Permeability coefficient and 
enhancement ratio were calculated using equation 2. 
 
 
A) The flux (Jss) (mg/cm2/h) was calculated from the slope of the plot of the cumulative amount of drug permeated per cm2 of 
skin at steady state against time using linear regression analysis.              
Jss = (dy/dx)ss x 1/A    --------------- (2) 
                           Where, (dy/dx)ss = Steady state slope and 
                          A= Effective diffusion area 
B) Permeability coefficient (P) were determined by using equation 3 [Krishnaiah Y.2008]. 
                                                               Steady State Flux (J) 
        Permeability (P) =   --------------------------------------------------                       -------------- (3) 
                                           Concentration of drug in donor solution (C) 
 
C) Enhancement ratio (ER) were determined by using following equation [Krishnaiah Y.2008]. 
                                                           Flux of drug with penetration enhancer 
            Enhancement ratio (ER) = -------------------------------------------                                  --------------- (4) 
                                                                      Flux of drug without penetration enhancer 
 
Table 2 Solvent systems, permeation enhancers for ex-vivo skin permeation studies of VH and polymeric nanoparticles of VH 
Sr. 
No. 
FC Solvent system Dose of VH 
(mg) 
PG 
(mL) 
EtoH 
(mL) 
DW 
(mL) 
PPNPs 
VH 
(mL) 
PE (%) 
1 W Water (Control) 37.5   2.0   
2 NPs Nanoparticles  37.5    2.0  
3 V1 33% EtoH in DW 37.5  0.7 1.3   
4 V2 50% EtoH in DW 37.5  1.0 1.0   
5 V3 66% EtoH in DW 37.5  1.3 0.7   
6 V4 100 % EtoH  37.5  2.0    
7 V5 33% PG in DW 37.5 0.7  1.3   
8 V6 50% PG in DW 37.5 1.0  1.0   
9 V7 66% PG in DW 37.5 1.3  0.7   
10 V8 100% PG 37.5 2.0     
11 V9 33% PG in EtoH 37.5 0.7 1.3    
12 V10 50% PG in EtoH 37.5 1.0 1.0    
13 V11 66% PG in EtoH 37.5 1.3 0.7    
14 V12 5% Cineole (50% PG in EtoH) 37.5     5%  
15 V13 5% Limonene (50% PG in EtoH) 37.5     5% 
16 V14 5% Menthol (50% PG in EtoH) 37.5     5% 
FC- Formulation code, VH- venlafaxine hydrochloride, PG- propylene glycol, EtOH- Ethanol, DW- Distilled water, PNPs VH- 
polymeric PLGA nanoparticles comprising VH, PE- Permeation enhancers 
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RESULTS AND DISCUSSION 
Experimental design 
The formulations were prepared as 9 sets using two 
variables following 32 factorial designs. VH loaded polymeric 
PLGA NPs were prepared by double emulsion solvent 
evaporation technique. The optimized formulations selected 
by the design were prepared and the parameters were 
compared to the expected values. The results are shown in 
table 3. For systematic investigation of the factors, a full 
factorial design was employed. 
 
Table 3 Optimization of formulation by using 32 full factorial design 
Formulation      
code 
Dose 
of  
VH 
Solvents 
DW: DCM 
(1:3)ratio 
Factor 1 Factor 2 Response 1 Response 2 Response 
3 
Response 4 
A: 
Concentration. 
of PLGA 
polymer 
B: 
Concentration 
of Tween-80 
surfactant 
 
Particle size PDI Zeta 
potential 
Entrapment 
efficiency 
mg mL mg %v/v nm - mV % 
F1 37.5 2 37.5 2.0 128.4 ±2.25 0.181 ±0.05 -6.8 ±0.26 36 ±3.12 
F2 37.5 2 37.5 0.5 78.2 ±1.96 0.103 ±0.03 -12.4 ±0.41 33 ±1.95 
F3 37.5 2 75 2.0 214.6 ±3.22 0.331 ±0.07 -15.2 ±0.32 45 ± .3.05 
F4 37.5 2 75 1.0 188.1 ±2.86 0.276 ±0.06 -14.3 ±0.54 43 ±2.68 
F5 37.5 2 75 0.5 163.8 ±2.94 0.243 ±0.03 -12.7 ±0.37 40 ±2.08 
F6 37.5 2 112.5 0.5 192.6 ±3.18 0.291 ±0.09 -10.2 ±0.30 47 ±1.12 
F7 37.5 2 37.5 1.0 97.6 ±1.37 0.137 ±0.05 -9.8 ±0.62 31 ±1.98 
F8 37.5 2 112.5 1.0 201.3 ±3.42 0.238 ±0.08 -10.5 ±0.29 51 ±2.14 
F9 37.5 2 112.5 2.0 175.4 
±1.48 
0.109 
±0.06 
-24.0 
±0.33 
56 ±3.56 
Data were expressed as mean ± SD (n=3) 
The effect on particle size (Y1) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 5. 
Y1 = 218.586 + 42.1048 * A + 11.8881 * B -18.7071 * AB - 
65.225 * A^2 -9.175 * B^2              ----------- (5) 
The terms A and B indicate concentrations of polymers PLGA 
and tween 80 respectively. As shown in equation 5, the 
positive sign with terms A and B indicated directly 
proportional relationship between concentration of 
polymers and particles size. As the concentrations of both 
polymers and surfactant were increased, the particles size 
was found to be increased. For response Y1 as shown in 
table 4, the coefficient of determination value (R2) was found 
to be 0.9880 indicating a good fit agreement between 
concentrations of polymers and particle size. The 3D surface 
response plot of particle size and its contour plot are shown 
in figure 1 (A) and (B) respectively. 
The effect on polydispersity index (Y2) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 6. 
Y2 = 0.314189 + 0.0283656 * A -0.0104677 * B -0.0702092 * 
AB -0.13375 * A^2 -0.00725 * B^2 ------ (6) 
The term A indicates concentration of PLGA whereas, term B 
indicates concentration of tween 80. By analyzing the 
equation, the positive response was observed for 
polydispersity index with PLGA. In case of tween 80, a 
negative response indicating the decreased polydispersity 
index was observed with decreased in tween 80 
concentration. The coefficient of determination was found to 
be value (R2) 0.9424 indicated the best fit agreement 
between effect of polymers on polydispersity index. The 3D 
surface response plot of polydispersity index and its contour 
plot are shown in figures 1 (C) and (D) respectively.      
The effect on zeta potential (Y3) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 7.   
Y3= -14.4046 -3.17049 * A -2.33716 * B -4.98444 * AB + 
2.9875 * A^2 -1.6 * B^2           ------------ (7) 
The term A indicates concentration of PLGA whereas term B 
indicates concentration of tween 80. By analyzing the 
equation, a negative response was observed for zeta 
potential with increasing concentration of tween 80 and 
PLGA. The coefficient of determination (R2) was found to be 
0.9524 indicating the good fit agreement between effects of 
polymers on particle size, PDI, zeta potential and 
entrapment efficiency. The 3D surface response plot of 
particle size, PDI, zeta potential and entrapment efficiency 
and its contour plot are shown in figures 1 (E) and (F) 
respectively. 
The effect on entrapment efficiency (Y4) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 8. 
Y4= 46.2385 + 9.14668 * A + 2.98002 * B + 1.32015 * AB -
3.75 * A^2 + 0.25 * B^2                        ------------ (8) 
The term A indicates concentration of PLGA whereas term B 
indicates concentration of tween 80. By analysing the 
equation, polymer and surfactant concentration were found 
to increase entrapment efficiency. The coefficient of 
determination (R2) was found to be 0.9614 indicating the 
good fit agreement between effects of polymers on particle 
size, PDI, zeta potential and entrapment efficiency. The 3D 
surface response plot of particle size, PDI, zeta potential and 
entrapment efficiency and its contour plot are shown in 
figures 1 (G) and (H) respectively. 
The p-values for particle size, PDI, Zeta potential and 
entrapment efficiency were found to be 0.004, 0.04 and 0.03 
and 0.005 respectively. Thus, the P-values were found to be 
significant.
 
Salve et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):505-518  
ISSN: 2250-1177                                                                                  [510]                                                                                 CODEN (USA): JDDTAO 
 
 
Fig. 1 3D response surface plot and contour plot of particle size, PDI, zeta potential and % EE of VH loaded PNPs 
(A) 3D response surface plot of particle size VH loaded PNPs 
(B) Contour plot of particle size VH loaded PNPs     (C) 3D 
response surface plot of PDI VH loaded PNPs (D) Contour 
plot of PDI VH loaded PNPs (E) 3D response surface plot of 
zeta potential VH loaded PNPs (F) Contour plot of zeta 
potential VH loaded PNPs (G) 3D response surface plot of % 
EE VH loaded PNPs (H) Contour plot of %EE VH loaded PNPs 
Characterization of VH loaded PNPs 
Determination of particle size, polydispersity index 
(PDI) and zeta potential 
The particle size and PDI of the VH loaded polymeric PLGA 
nanoparticles are important characters in determining the 
capability of the particles to cross the BBB. The particle size 
and PDI of formulations (F1-F9) were obtained using 
Zetasizer Nano ZS 90 and the results are depicted in table 4 
and particle size and PDI of optimized formulation F9 is 
shown in Fig. 2. 
Table 4 Evaluations of particle size and PDI of formulations 
F1-F9 
Sr. 
No. 
Formulations Particle Size (nm) PDI 
1 F1 128.4 ±2.25 0.181 ±0.05 
2 F2 78.2 ±1.96 0.103 ±0.03 
3 F3 214.6 ±3.22 0.331 ±0.07 
4 F4 188.1 ±2.86 0.276 ±0.06 
5 F5 163.8 ±2.94 0.243 ±0.03 
6 F6 192.6 ±3.18 0.291 ±0.09 
7 F7 97.6 ±1.37 0.137 ±0.05 
8 F8 201.3 ±3.42 0.238 ±0.08 
9 F9 175.4 ±1.48 0.109 ±0.06 
Data were expressed as mean ± SD (n=3) 
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Fig. 2 Particle size and PDI of optimized formulation F9 
Determination of zeta potential 
The zeta potential of the polymeric nanoparticles is 
important to determine the stability and uptake mechanism 
of the particles inside the body. The zeta potential of the 
formulations F1-F9 is shown in table 5 and zeta potential of 
optimized formulation F9 is shown in fig. 3.  
Table 5 Evaluations of Zeta potential (F1-F9) 
Sr. No. Formulation code Zeta potential (mV) 
1 F1 -6.8 ±0.26 
2 F2 -12.4 ±0.41 
3 F3 -15.2 ±0.32 
4 F4 -14.3 ±0.54 
5 F5 -12.7 ±0.37 
6 F6 -10.2 ±0.30 
7 F7 -9.8 ±0.62 
8 F8 -10.5 ±0.29 
9 F9 -24.0 ±0.33 
Data were expressed as mean ± SD (n=3)
 
 
 
Fig. 3 Zeta potential of optimized formulation F9 
 
Determination of percent entrapment efficiency  
The results of percent entrapment efficiency and percent 
drug loading of formulations F1-F9 are shown in table 6.  
Table 6 Formulations of percent entrapment efficiency of 
formulations F1-F9 
Sr. No. Formulation 
code 
% Entrapment 
efficiency 
1 F1 36 ±3.12 
2 F2 33 ±1.95 
3 F3 45 ± .3.05 
4 F4 43 ±2.68 
5 F5 40 ±2.08 
6 F6 47 ±1.12 
7 F7 31 ±1.98 
8 F8 51 ±2.14 
9 F9 56 ±3.56 
Data were expressed as mean ± SD (n=3) 
FT-IR spectroscopy  
The FT-IR spectra of VH, PLGA polymer and VH loaded 
polymeric PLGA nanoparticles (fig. 4 (A), (B), (C) 
respectively) were recorded from 400-4000 cm-1, The KBr 
press plate technique was used to prepare sample. The ratio 
of VH to PLGA polymers was kept at 1:100 for preparation of 
sample. The FT-IR spectrum of VH shown peaks 1244.11 cm-
1 (C-O-C stretching), 1450 cm-1 (-CH3 bend), 1375 cm-1 (-CH3 
bend,) 1465 (-CH2 bend), 1600 cm-1 (C=C aromatic stretch), 
2835.41 cm-1 (cyclic aliphatic -CH stretch), 3328.3 cm-1 (-OH 
alcohol H-bonded). FT-IR spectrum of PLGA polymer shown 
the peaks 2358.98 cm-1(C=O),  1749.47 cm-1 (C=O), 1457.25 
cm-1 (C-O), 1273.04 cm-1 (C-C), 2876.88 cm-1 (-CH3 
symmetric),  2946.32 cm-1 (-CH3 Asymmetric), 3647.45 cm-1 
(O-H), 2876.88 cm-1 (C-H symmetric), 2946.32 cm-1 (C-H 
Asymmetric). The FT-IR spectrum of VH loaded polymeric 
PLGA NPs shown the peaks 2946.32 cm-1 (C-H asymmetric 
stretch), 1448.57 cm-1 (-CH3 bend). 
 
 
Salve et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):505-518  
ISSN: 2250-1177                                                                                  [512]                                                                                 CODEN (USA): JDDTAO 
 
Fig. 4 FT-IR spectrum of VH, PLGA and VH loaded PPNPs(A) FT-IR spectrum of VH (B) FT-IR spectrum of PLGA (C) FT-IR 
spectrum of VH loaded PNPs 
 
Differential scanning colorimetry 
The DSC thermogram of VH, PLGA and VH loaded PPNPs 
(shown in fig. 5 (A), (B), (C) respectively) were recorded 
SHIMADZU DSC instrument. The heating rate was kept at 5 
°C/min. up to 300 °C. The DSC thermogram of VH shown the 
onset of melting process at 210.64 °C and endset at 214.32 
°C. A sharp melting peak was observed at 211.97 °C which 
was found to be near to the reported value 215-217 °C as 
melting point range of VH. The enthalpy for the endothermic 
transition was found to be (-) 64.90 J/g. PLGA polymer 
shown the onset of melting point at 43.6 °C and end set at 
48.39 °C with glass transition temperature at 46.40 °C which 
was found to be as per the reported value of glass transition 
temperature for PLGA at 44-48 °C. The VH loaded PNPs were 
subjected to DSC analysis. It showed the onset at 42.21 °C 
and endset at 46.94 °C with an endothermic peak 44.48 °C 
which was found to be similar to glass transition 
temperature of PLGA polymer. The absence of endothermic 
transition of VH indicated the coating of drug due to 
formation of polymeric nanoparticles. 
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Fig. 5 DSC thermogram of VH, PLGA and VH loaded PNPs(A) DSC thermogram of VH (B) DSC thermogram of     PLGA (C) DSC 
thermogram of VH loaded PNPs 
 
X ray diffraction spectroscopy study  
The powder x-ray diffraction spectrum of VH, PLGA polymer 
and VH loaded PLGA nanoparticles were reported at an 
angle 2θ (Fig. 6). The following sharp peaks with intensities 
were observed at an angle 2θ at 6.82, 8.15, 10.34, 12.83, 
13.62, 15.13, 17.44, 18.35, 19.88, 21.32, 21.85, 22.61, 22.89, 
25.19, 26.43, 27.33, 28.68, 31.22, 33.35, 34.14, 35.20, 37.77. 
The sharp crystalline peaks at an angle 2θ confirmed the 
crystalline characteristics of VH. In case PLGA polymer the 
diffused pattern was observed and no sharp crystalline peak 
was present in the x-ray diffraction spectra. It indicating 
amorphous characteristics of the PLGA polymer. VH loaded 
polymeric PLGA nanoparticles has shown a diffused pattern 
in the X-RD spectra. It indicating the formation of 
nanoparticles. The PLGA polymer coat being present on drug 
molecule, hence the crystalline characteristics of VH was not 
observed in X-ray diffraction spectrum of polymeric NPs as 
shown in fig. 6 (A), (B), (C) respectively. 
 
 
 
Salve et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):505-518  
ISSN: 2250-1177                                                                                  [514]                                                                                 CODEN (USA): JDDTAO 
 
A 
 
B 
 
C 
Fig. 6 X-RD spectrum of VH, PLGA and VH loaded PNPs (A) X-RD spectrum of VH (B) X-RD spectrum of PLGA (C) X-RD spectrum 
of VH loaded PNPs 
Surface morphology study 
Scanning electron microscopy of lyophilized VH loaded 
polymeric PLGA nanoparticles is shown in fig 7. A well-
formed spherical polymeric nanoparticles containing VH 
were observed. 
Ex-vivo permeation study 
The ex-vivo permeation study VH was carried using ethanol, 
propylene glycol and their binary combinations with distilled 
water in various proportions and penetration enhancers 
were studied for their effect on skin permeation (Table 7).  
Table 7 Ex-vivo effect of the solvent systems, permeation 
enhancers and nanoparticles on lag time, flux, and 
permeation parameters of VH 
 
Fig. 7 Scanning electron microscopy study of VH loaded 
polymeric PLGA nanoparticles
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Table 7 Ex-vivo effect of the solvent systems, permeation enhancers and nanoparticles on lag time, flux, and permeation 
parameters of VH 
Sr. No. FC SS 
PE 
PNPs 
Lag time 
(h.) 
Flux 
(µg/cm2/h) 
 
 
Steady state 
permeability 
coefficient 
(Kp) (cm/h) 
Enhancement  
ratio 
             (ER) 
1 W DW (Control) 6.22±0.26 79.65±1.2 2.12 1.0 
2 NPs Nanoparticles 4.22±0.14 192.24±3.6 5.12 2.41 
3 V1 33% EtoH in DW 5.80±0.19 114.75±1.9 3.06 1.44 
4 V2 50% EtoH in DW 5.58±0.15 137.08±2.7 3.65 1.72 
5 V3 66% EtoH in DW 5.49±0.20 142.30±2.9 3.79 1.78 
6 V4 100 % EtoH 6.00±0.28 118.29±2.6 3.15 1.48 
7 V5 33% PG in DW 5.86±0.21 106.41±2.1 2.83 1.33 
8 V6 50% PG in DW 5.73±0.13 111.69±2.5 2.97 1.40 
9 V7 66% PG in DW 5.62±0.26 122.78±2.8 3.27 1.54 
10 V8 100% PG 6.12±0.34 85.82±1.0 2.28 1.07 
11 V9 33% PG in EtoH 5.52±0.23 150.22±1.9 4.00 1.88 
12 V10 50% PG in EtoH 5.60±0.16 158.67±2.9 4.23 1.99 
13 V11 66% PG in EtoH 6.00±0.28 147.05±2.7 3.92 1.84 
14 V12 5% Cineole (50% PG 
in EtoH) 
5.77±0.17 177.20±3.4 4.72 2.22 
15 V13 5% Limonene (50% 
PG in EtoH) 
3.17±0.11 200.47±3.6 5.34 2.51 
16 
 
V14 5% Menthol (50% 
PG in EtoH) 
5.90±0.19 163.52±2.9 4.36 2.05 
Data were expressed as Mean ± SD (n=3) 
FC- Formulation code, SS-solvent system, PE-permeation enhancers, PNPs- polymeric poly (lactic co-glycolic acid), DW- distilled 
water, PG- propylene glycol, EtOH- Ethanol, Kp- Permeability coefficient, ER-Enhancement ratio 
 
In the ex-vivo skin permeation studies of VH using distilled 
water as solvent system shown the lag time 6.22 h and flux 
value 79.65 µg/cm2/h was observed and was treated as 
control. The binary combinations of ethanol 33% to 66% in 
distilled water has shown decreased lag times (5.80±0.19, 
5.58±0.15 5.49±0.20) and the flux values were found to be 
increased (114.75±1.9, 137.08±2.7, 142.30±2.9). At 100% 
ethanol, lag time was found to be further enhanced (6.00± 
0.28 h) and the flux value was also reduced (118.29±2.6) as 
compared to 66% ethanol in distilled water and control. 
Since VH is water soluble drug, the increasing concentration 
of ethanol may have increased the bilayer fluidity which can 
be explained by the increased in rate and amplitude of 
translational and rotational motion of individual of -CH 
group of acyl chain of lipids of stratum corneum. The 
increased lag time at 100% ethanol concentration may be 
due to dehydration of skin which results in increased 
tortuosity of diffusion pathway (Bommanan et al.1991). As 
compared to control, in case of ethanol lag time was found to 
be higher but was decreased with increasing ethanol 
concentration up to 66% as shown in fig.8 (A), (B), (C) 
respectively.
 
 
Fig. 8 Effect of solvent system on (A) amount of drug permeation (B) flux (C) lag time (33% - 100% EtOH in DW) 
 
Propylene glycol in distilled water in concentration 33 to 
66% shown decreased lag time values (5.86 ±0.21, 5.73 ± 
0.13, 5.62 ±0.26) and the lag time value was found to be 
lower than control (6.22 ± 026) and at 100% PG the 
maximum lag time was observed (6.12 ±0.34) (Table 7). 
Similarly, the flux value was found to increase (106.41± 2.1, 
111.69± 2.5, 122.78.28±2.8) from 33% to 66% PG in distilled 
water but the flux was decreased (85.82±1.0) at 100% PG as 
shown in Fig.9 (A), (B), (C) respectively. It is due to 
hygroscopic nature of PG, since PG forms pools inside skin, 
thereby leading to dehydration of skin (Ostrenga et al. 
1971). The pool formation in skin is expected at all 
concentrations of PG but at 100% PG free water present was 
negligible to satisfy the hydration requirement of PG. Thus at 
100% PG extracts water from skin bilayers and corneocytes 
pockets and leading to increasing in barrier property of 
stratum corneum. 
Salve et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):505-518  
ISSN: 2250-1177                                                                                  [516]                                                                                 CODEN (USA): JDDTAO 
 
Fig. 9 Effect of solvent system on (A) amount of drug permeation (B) flux (C) lag time (33% to 100% PG in DW) 
 
The lag time in binary combinations of propylene glycol in 
ethanol in 33, 50, and to 66% were found 5.52±0.23, 
5.60±0.16, 6.00±028 respectively. The lag time was found to 
increase with increasing concentration of PG in ethanol. The 
flux value in 33, 50, and to 66% PG in ethanol were found to 
be 150.22±1.9, 158.67 ± 2.9, 147.05 ± 2.7 µg/cm2/h. With 
the binary combination 33% and 50% PG in ethanol, flux 
were found to be enhanced but at 66% PG in ethanol the flux 
was further decreased as shown in fig. 10 (A), (B), (C) 
respectively.
 
 
Fig. 10 Effect of solvent system on (A) amount of drug permeation (B) flux (C) lag time (33 -66% PG in EtOH) 
 
d) From above solvent systems, the solvent systems 
comprising 50% propylene glycol in ethanol shown 
maximum flux value and minimum lag time as compared to 
control. Hence the effect of penetration enhancers cineole, 
limonene, and menthol in 5 % concentrations were studied 
in the above solvent system. The minimum lag time value 
was observed with 5% limonene in 50% PG in ethanol and 
shown the highest flux (200.47 ± 3.6) than control 
(79.65±1.2) as shown in Table 7 and fig. 11(A), (B), (C) 
respectively. Hence, we can conclude that the above solvent 
system can be used for the transdermal drug delivery of VH.
  
 
Fig. 11 Effect of permeation enhancers on (A) amount of drug permeation (B) flux (C) lag time (5% PE) 
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The meaningful plasma level concentrations can be achieved 
by taking considerations by flux value, clearance value of 
drug and surface area of transdermal patch. 
Pharmacokinetic parameters of VH 
CL = 1.3 ± 0.6 liter/hour/kg  
Vd = 7.5 ± 3.7 liter/kg 
T1/2 = 5 ± 2 hours 
BA = 42 ± 15 %                     
C = (Ja x Sa)/CL 
Where, C = Steady state plasma Concentration 
             Ja = Flux  
             Sa = Surface area 
            CL = Clearance  
The maximum flux achieved was 200.47 [µg/cm2/hr] 
                C = (Ja x Sa)/CL  
                       
                         200.47 [µg/cm2/h x Sa [cm2] 
            C =    ---------------------------------------- 
                              78,000 [mL/h] 
 
Steady state concentrations of VH from 12.85 ng/mL to 
128.5 ng/mL can be obtained with patch size of 5 cm2 to 50 
cm2 respectively shown in table 8. 
Table 8 Steady state concentration of VH 
Sr. No. Surface area of 
patch (cm2) 
Steady state plasma 
level of VH (ng/mL) 
1 5 12.85 
2 10 25.70 
3 20 51.40 
4 30 77.10 
5 40 102.8 
6 50 128.5 
 
CONCLUSION 
Nanoparticles represent a tool to transport the necessarily 
drugs across the BBB that normally are unable to cross this 
barrier. Drug that have successfully have been transported 
into the brain using this carrier include polymeric poly 
(lactic co-glycolic acid). Tween-80 was used as surfactant in 
nanoparticle formulation.  
Ex-vivo skin permeation study of VH was carried out in 
different solvent systems and results indicated that solvent 
system comprising 50 % PG in ethanol shown maximum flux 
of 158.67 ±2.9 µg/cm2/h and lag time 5.60 ±0.16 h, 
maximum permeability coefficient 4.23 cm/h and maximum 
enhancement ratio 1.99 was observed as compared to other 
solvent systems studied. 
Ex-vivo skin permeation study of VH was carried out in 
different PEs and results indicated that 5%v/v limonene 
shown maximum flux 200.47 ±3.6 µg/cm2/h and least lag 
time of 3.17 ±0.11 h, maximum permeability coefficient 5.34 
cm/h and maximum enhancement ratio 2.51 was observed 
as compared to other PEs. The rank order was observed for 
skin permeation of VH in different PEs: limonene > cineole > 
menthol. Limonene was increasing partitioning of a drug into 
stratum corneum which leads to increased permeation rate 
of drug. 
Ex-vivo skin permeation study of VH -PPNPs was carried out 
and compared with control group (distilled water) and 
results indicated that VH -PPNPs shown maximum flux of 
192.24 ±3.6 µg/cm2/h and least lag time 4.22 ±0.14 h, 
maximum permeability coefficient 5.12 cm/h and maximum 
enhancement ratio 2.41 was observed as compared to 
control group (distilled water).  
From the above observation, it was concluded that 
combination of optimized solvent system (50% PG in 
ethanol), optimized PE (5 %v/v limonene) and VH-PPNPs 
may be choice for use in a novel transdermal formulation of 
VH. 
Based on the clearance value of VH (78000 mL/h), maximum 
flux value obtained 200.47 ±2.54 (µg/cm2/h) and by varying 
the surface area of the transdermal patch from 5cm2 to 50 
cm2, a meaningful plasma level concentration of VH ranging 
from 12.85 to128.5 ng/mL can be achieved. 
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